IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice

被引:96
作者
Chmiel, JF
Konstan, MW
Knesebeck, JE
Hilliard, JB
Bonfield, TL
Dawson, DV
Berger, M
机构
[1] Rainbow Babies & Childrens Hosp, Div Pediat Immunol, Dept Pediat, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Epidemiol & Biostat, Cleveland, OH USA
关键词
D O I
10.1164/ajrccm.160.6.9901043
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Cystic fibrosis (CF) lung disease is characterized by an excessive inflammatory response associated with chronic Pseudomonas aeruginosa endobronchial infection. Compared with bronchoalveolar lavage fluid from healthy subjects, lavage fluid from patients with CF contains elevated proinflammatory cytokines but negligible amounts of the anti-inflammatory cytokine interleukin-10 (IL-10). We sought to determine whether IL-10 deficiency results in increased local and systemic morbidity in mice with chronic endobronchial infection with P. aeruginoso embedded in agar beads and to determine if exogenous IL-10 might reduce these effects. infected IL-10 knockout mice had more severe weight loss (p = 0.04) and increased area of lung inflammation (28 +/- 4 versus 10 +/- 2%, p < 0.002) but no alterations in bacterial burden compared with wild-type mice. Infected CD-1 mice treated with IL-10 had improved survival (p = 0.035), less severe weight loss (p < 0.005), fewer bronchoalveolar lavage neutrophils (3 x 10(5)/ml versus 5 x 10(6)/ml, p < 0.02), and decreased area of lung inflammation (11 +/- 2 versus 35 +/- 7%, p < 0.01) but no alterations in bacterial burden compared with placebo-treated mice. These data suggest that IL-10 is an important regulator of the inflammatory response to P. aeruginosa endobronchial infection and that further investigation into the use of IL-10 in CF is warranted.
引用
收藏
页码:2040 / 2047
页数:8
相关论文
共 37 条
  • [11] A MULTICENTER STUDY OF ALTERNATE-DAY PREDNISONE THERAPY IN PATIENTS WITH CYSTIC-FIBROSIS
    EIGEN, H
    ROSENSTEIN, BJ
    FITZSIMMONS, S
    SCHIDLOW, DV
    BECKERMAN, R
    CANNY, G
    CAPLAN, D
    FINK, R
    GLASSER, L
    HARLEY, F
    HSU, J
    LAPEY, A
    LEWISTON, N
    PALMER, J
    LYRENE, R
    BRASFIELD, D
    NIELSON, D
    PRESTIDGE, C
    [J]. JOURNAL OF PEDIATRICS, 1995, 126 (04) : 515 - 523
  • [12] FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
  • [13] NONPARAMETRIC METHODS IN LONGITUDINAL STUDIES
    GHOSH, M
    GRIZZLE, JE
    SEN, PK
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1973, 68 (341) : 29 - 36
  • [14] GREENBERGER MJ, 1995, J IMMUNOL, V155, P722
  • [15] KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075
  • [16] Konstan M.W., 1993, CYSTIC FIBROSIS, V64, P219
  • [17] EFFECT OF HIGH-DOSE IBUPROFEN IN PATIENTS WITH CYSTIC-FIBROSIS
    KONSTAN, MW
    BYARD, PJ
    HOPPEL, CL
    DAVIS, PB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (13) : 848 - 854
  • [18] Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.3.CO
  • [19] 2-4
  • [20] IBUPROFEN ATTENUATES THE INFLAMMATORY RESPONSE TO PSEUDOMONAS-AERUGINOSA IN A RAT MODEL OF CHRONIC PULMONARY INFECTION - IMPLICATIONS FOR ANTIINFLAMMATORY THERAPY IN CYSTIC-FIBROSIS
    KONSTAN, MW
    VARGO, KM
    DAVIS, PB
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (01): : 186 - 192